Alkermes: Demonstrating Value
You may also be interested in...
Alkermes’ focus on mental illnesses, substance abuse and other CNS disorders could gain a boost from essential health benefit and mental health parity provisions of the law.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."